These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 34843980)

  • 1. Sodium-glucose cotransporter type 2 inhibitors prevent ponatinib-induced endothelial senescence and disfunction: A potential rescue strategy.
    Madonna R; Barachini S; Moscato S; Ippolito C; Mattii L; Lenzi C; Balistreri CR; Zucchi R; De Caterina R
    Vascul Pharmacol; 2022 Feb; 142():106949. PubMed ID: 34843980
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Empagliflozin mitigates ponatinib-induced cardiotoxicity by restoring the connexin 43-autophagy pathway.
    Mattii L; Moscato S; Ippolito C; Polizzi E; Novo G; Zucchi R; De Caterina R; Ghelardoni S; Madonna R
    Biomed Pharmacother; 2024 Sep; 178():117278. PubMed ID: 39116784
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na
    Uthman L; Baartscheer A; Bleijlevens B; Schumacher CA; Fiolet JWT; Koeman A; Jancev M; Hollmann MW; Weber NC; Coronel R; Zuurbier CJ
    Diabetologia; 2018 Mar; 61(3):722-726. PubMed ID: 29197997
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Empagliflozin and Dapagliflozin Reduce ROS Generation and Restore NO Bioavailability in Tumor Necrosis Factor α-Stimulated Human Coronary Arterial Endothelial Cells.
    Uthman L; Homayr A; Juni RP; Spin EL; Kerindongo R; Boomsma M; Hollmann MW; Preckel B; Koolwijk P; van Hinsbergh VWM; Zuurbier CJ; Albrecht M; Weber NC
    Cell Physiol Biochem; 2019; 53(5):865-886. PubMed ID: 31724838
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sodium-Glucose CoTransporter-2 Inhibitor Empagliflozin Ameliorates Sunitinib-Induced Cardiac Dysfunction via Regulation of AMPK-mTOR Signaling Pathway-Mediated Autophagy.
    Ren C; Sun K; Zhang Y; Hu Y; Hu B; Zhao J; He Z; Ding R; Wang W; Liang C
    Front Pharmacol; 2021; 12():664181. PubMed ID: 33995090
    [No Abstract]   [Full Text] [Related]  

  • 6. Cardioprotection by selective SGLT-2 inhibitors in a non-diabetic mouse model of myocardial ischemia/reperfusion injury: a class or a drug effect?
    Nikolaou PE; Mylonas N; Makridakis M; Makrecka-Kuka M; Iliou A; Zerikiotis S; Efentakis P; Kampoukos S; Kostomitsopoulos N; Vilskersts R; Ikonomidis I; Lambadiari V; Zuurbier CJ; Latosinska A; Vlahou A; Dimitriadis G; Iliodromitis EK; Andreadou I
    Basic Res Cardiol; 2022 May; 117(1):27. PubMed ID: 35581445
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential In Vitro Effects of SGLT2 Inhibitors on Mitochondrial Oxidative Phosphorylation, Glucose Uptake and Cell Metabolism.
    Zügner E; Yang HC; Kotzbeck P; Boulgaropoulos B; Sourij H; Hagvall S; Elmore CS; Esterline R; Moosmang S; Oscarsson J; Pieber TR; Peng XR; Magnes C
    Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887308
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Empagliflozin inhibits excessive autophagy through the AMPK/GSK3β signalling pathway in diabetic cardiomyopathy.
    Madonna R; Moscato S; Cufaro MC; Pieragostino D; Mattii L; Del Boccio P; Ghelardoni S; Zucchi R; De Caterina R
    Cardiovasc Res; 2023 May; 119(5):1175-1189. PubMed ID: 36627733
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Empagliflozin improved systolic blood pressure, endothelial dysfunction and heart remodeling in the metabolic syndrome ZSF1 rat.
    Park SH; Farooq MA; Gaertner S; Bruckert C; Qureshi AW; Lee HH; Benrahla D; Pollet B; Stephan D; Ohlmann P; Lessinger JM; Mayoux E; Auger C; Morel O; Schini-Kerth VB
    Cardiovasc Diabetol; 2020 Feb; 19(1):19. PubMed ID: 32070346
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Empagliflozin and Dapagliflozin Increase Na
    Dago M; Crespo-García T; Cámara-Checa A; Rapún J; Rubio-Alarcón M; Marín M; Tamargo J; Caballero R; Delpón E
    Cells; 2022 Nov; 11(23):. PubMed ID: 36496967
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sex-related differential susceptibility to ponatinib cardiotoxicity and differential modulation of the Notch1 signalling pathway in a murine model.
    Madonna R; Pieragostino D; Cufaro MC; Del Boccio P; Pucci A; Mattii L; Doria V; Cadeddu Dessalvi C; Zucchi R; Mercuro G; De Caterina R
    J Cell Mol Med; 2022 Mar; 26(5):1380-1391. PubMed ID: 35122387
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sodium-glucose cotransporter 2 inhibitors antagonize lipotoxicity in human myeloid angiogenic cells and ADP-dependent activation in human platelets: potential relevance to prevention of cardiovascular events.
    Spigoni V; Fantuzzi F; Carubbi C; Pozzi G; Masselli E; Gobbi G; Solini A; Bonadonna RC; Dei Cas A
    Cardiovasc Diabetol; 2020 Apr; 19(1):46. PubMed ID: 32264868
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dedicated kidney disease-focused outcome trials with sodium-glucose cotransporter-2 inhibitors: Lessons from CREDENCE and expectations from DAPA-HF, DAPA-CKD, and EMPA-KIDNEY.
    Rhee JJ; Jardine MJ; Chertow GM; Mahaffey KW
    Diabetes Obes Metab; 2020 Apr; 22 Suppl 1(Suppl 1):46-54. PubMed ID: 32267076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autophagic flux inhibition enhances cytotoxicity of the receptor tyrosine kinase inhibitor ponatinib.
    Corallo D; Pastorino F; Pantile M; Mariotto E; Caicci F; Viola G; Ponzoni M; Tonini GP; Aveic S
    J Exp Clin Cancer Res; 2020 Sep; 39(1):195. PubMed ID: 32962733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SGLT2 inhibition via dapagliflozin improves generalized vascular dysfunction and alters the gut microbiota in type 2 diabetic mice.
    Lee DM; Battson ML; Jarrell DK; Hou S; Ecton KE; Weir TL; Gentile CL
    Cardiovasc Diabetol; 2018 Apr; 17(1):62. PubMed ID: 29703207
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sodium-Glucose Cotransporter-2 inhibitors are potential therapeutic agents for treatment of non-diabetic heart failure patients.
    Nakagawa Y; Kuwahara K
    J Cardiol; 2020 Aug; 76(2):123-131. PubMed ID: 32340780
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Direct Cardiac Actions of Sodium Glucose Cotransporter 2 Inhibitors Target Pathogenic Mechanisms Underlying Heart Failure in Diabetic Patients.
    Uthman L; Baartscheer A; Schumacher CA; Fiolet JWT; Kuschma MC; Hollmann MW; Coronel R; Weber NC; Zuurbier CJ
    Front Physiol; 2018; 9():1575. PubMed ID: 30519189
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined SGLT2 and DPP4 Inhibition Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Nephropathy in Mice with Type 2 Diabetes.
    Birnbaum Y; Bajaj M; Yang HC; Ye Y
    Cardiovasc Drugs Ther; 2018 Apr; 32(2):135-145. PubMed ID: 29508169
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glycemic control by the SGLT2 inhibitor empagliflozin decreases aortic stiffness, renal resistivity index and kidney injury.
    Aroor AR; Das NA; Carpenter AJ; Habibi J; Jia G; Ramirez-Perez FI; Martinez-Lemus L; Manrique-Acevedo CM; Hayden MR; Duta C; Nistala R; Mayoux E; Padilla J; Chandrasekar B; DeMarco VG
    Cardiovasc Diabetol; 2018 Jul; 17(1):108. PubMed ID: 30060748
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sodium-Glucose Cotransporter 2 Inhibitors in Patients with Non-Diabetic Chronic Kidney Disease.
    Mima A
    Adv Ther; 2021 May; 38(5):2201-2212. PubMed ID: 33860925
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.